Raltegravir cerebrospinal fluid concentrations in HIV-1 infection

PLoS ONE

Volumn 4, Issue 9, 2009, Pages

  Yilmaz, Aylin ^a   Gisslén, Magnus ^a   Spudich, Serena ^b   Lee, Evelyn ^b   Jayewardene, Anura ^b   Aweeka, Francesca ^b   Price, Richard W ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; ETHAMBUTOL; RALTEGRAVIR; RIFABUTIN; 2 PYRROLIDONE DERIVATIVE; ALBUMINOID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIQUID CHROMATOGRAPHY; MALE; MYCOBACTERIOSIS; TANDEM MASS SPECTROMETRY; BIOSYNTHESIS; BLOOD; CEREBROSPINAL FLUID; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ALBUMINS; ANTI-HIV AGENTS; CHROMATOGRAPHY, LIQUID; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PYRROLIDINONES; REPRODUCIBILITY OF RESULTS;

EID: 70149119217     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006877     Document Type: Article

References (16)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860.
2. d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, et al. (2004) Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 55: 320-328.
3. Price RW, Spudich S (2008) Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis 197 Suppl 3: S294-306.
4. Gisslén M, Hagberg L, Rosengren L, Brew BJ, Cinque P, et al. (2006) Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacology: in press.
5. Cocohoba J, Dong BJ (2008) Raltegravir: the first HIV integrase inhibitor. Clin Ther 30: 1747-1765.
6. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, et al. (2008) Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 359: 339-354.
7. Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, et al. (2008) Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 83: 293-299.
8. Letendre S, Capparelli E, Best B, Clifford D, Collier AC, et al. (2006) Better Antiretroviral Penetration into the Central Nervous System Is Associated with Lower CSF Viral Load. Presented at: Conference of Retroviruses and Opportunistic Infections, Denver.
9. Varatharajan L, Thomas SA (2009) The transport of anti-HIV drugs across blood-CNS interfaces: Summary of current knowledge and recommendations for further research. Antiviral Res.
10. Price RW, Staprans S (1997) Measuring the "viral load" in cerebrospinal fluid in human immunodeficiency virus infection: window into brain infection? Ann Neurol 42: 675-678.
11. Tibbling G, Link H, Ohman S (1977) Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J clin Lab Invest 37: 385-390.
12. Wenning L, Petry A, Kost J, Jin B, Breidinger S, et al. (2009) Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms. Clin Pharmacol Ther.
13. Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, et al. (2007) Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 35: 1657-1663.
14. (2008)http://www.merck.com/product/usa/pi_circulars/i/isentress/ isentress_pi.pdf.
15. Power C, Kong PA, Crawford TO, Wesselingh S, Glass JD, et al. (1993) Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier. Ann Neurol 34: 339-350.
16. Sinclair E, Ronquillo R, Lollo N, Deeks SG, Hunt P, et al. (2008) Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr 47: 544-552.